Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 4
- Registration Number
- NCT02110147
- Locations
- 🇺🇸
Children's Hospital of Michigan - Specialty Center Detroit, Detroit, Michigan, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination
- Conditions
- Toxicity Due to Chemotherapy
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Wellstat Therapeutics
- Registration Number
- NCT01432301
Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2005-05-16
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT00110864
- Locations
- 🇺🇸
Phoenix Internal Medicine Associates, Waterbury, Connecticut, United States
🇺🇸Center for Diabetes and Endocrine Care, Hollywood, Florida, United States
🇺🇸Genesis Research International, Longwood, Florida, United States
Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2005-05-16
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT00110851
- Locations
- 🇺🇸
Phoenix Internal Medicine Associates, Waterbury, Connecticut, United States
🇺🇸University Clinical Research-DeLand, DeLand, Florida, United States
🇺🇸Center for Diabetes and Endocrine Care, Hollywood, Florida, United States
Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer
- Conditions
- Drug/Agent Toxicity by Tissue/OrganPancreatic Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-06-28
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 250
- Registration Number
- NCT00024427
- Locations
- 🇺🇸
Brookwood Medical Center, Birmingham, Alabama, United States
🇺🇸Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
- Prev
- 1
- 2
- Next